RUNX1 mutations correlate with response to venetoclax combination therapies in relapsed/refractory acute myeloid leukemia

被引：5

作者：

Chow, Signy ^{[1
]}

Tang, Kenny ^{[2
]}

Al-Abri, Mahmood ^{[2
]}

Hall, Victoria ^{[3
]}

Tremblay-Lemay, Rosemarie ^{[4
,5
]}

Rashedi, Iran ^{[6
]}

Tsui, Hubert ^{[7
,8
]}

Chan, Steven M. ^{[9
]}

机构：

[1] Sunnybrook Hlth Sci Ctr, Div Med Oncol & Hematol, Dept Med, Toronto, ON, Canada

[2] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

[3] Univ Hlth Network, Transplant Infect Dis & Ajmera Transplant Ctr, Toronto, ON, Canada

[4] Toronto Gen Hosp, Univ Hlth Network, Lab Med Program, Toronto, ON, Canada

[5] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[6] Sunnybrook Hlth Sci Ctr, Div Hematol Pathol, Dept Lab Med & Mol Diagnost, Toronto, ON, Canada

[7] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada

[8] Sunnybrook Hlth Sci Ctr, Div Hematol Pathol, Dept Lab Med & Mol Diagnost, Toronto, ON, Canada

[9] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada

来源：

LEUKEMIA RESEARCH | 2021年 / 111卷

关键词：

D O I：

10.1016/j.leukres.2021.106735

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：4

共 50 条

[1] Venetoclax Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia
Brancati, Serena
Gozzo, Lucia
Romano, Giovanni Luca
Vetro, Calogero
Dulcamare, Ilaria
Maugeri, Cinzia
Parisi, Marina
Longo, Laura
Vitale, Daniela Cristina
Di Raimondo, Francesco
Drago, Filippo
BLOOD, 2021, 138
[2] Venetoclax in combination with azacitidine or decitabine in relapsed/refractory acute myeloid leukemia
Che, Yue
Tan, Wanqing
Liu, Ying
Liu, Haitao
Li, Lanlan
Qin, Fangmei
TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2024, 23 (01) : 209 - 214
[3] Chidamide in Combination With DCAG With or Without Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia
Liu, Qingyang
Zhang, Xiawei
Lv, Lei
Xu, Linming
Jing, Yu
Gao, Wenjing
Wang, Lili
Dou, Liping
CANCER MEDICINE, 2025, 14 (05):
[4] Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia
Aldoss, Ibrahim
Yang, Dongyun
Aribi, Ahmed
Ali, Haris
Sandhu, Karamjeet
Al Malki, Monzr M.
Mei, Matthew
Salhotra, Amandeep
Khaled, Samer
Nakamura, Ryotaro
Snyder, David
O'Donnell, Margaret
Stein, Anthony S.
Forman, Stephen J.
Marcucci, Guido
Pullarkat, Vinod
HAEMATOLOGICA, 2018, 103 (09) : E404 - E407
[5] Pegcrisantaspase in Combination with Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia: A Phase 1 Study
Niyongere, Sandrine
Duong, Vu H.
Bollino, Dominique R.
Lapidus, Rena G.
Strovel, Erin T.
Zarrabi, Jinoos
Bah, Osman Mohamed
Philip, Sunita
Kflu, Veronica
Baer, Maria R.
Emadi, Ashkan
BLOOD, 2021, 138
[6] Combination of Homoharringtonine with Venetoclax and Azacitidine Excerts Better Treatment Response in Relapsed/Refractory Acute Myeloid Leukemia
Yu, Guopan
Xu, Na
Huang, Fen
Fan, Zhiping
Liu, Hui
Shi, Pengcheng
Zhou, Hongsheng
Wang, Zhixiang
Zhang, Yu
Liu, Qifa
BLOOD, 2020, 136
[7] RUNX1 Mutations Reduce the Expression of CEBPA in Acute Myeloid Leukemia
Grossmann, Vera
Kohlmann, Alexander
Dicker, Frank
Butschalowski, Katrin
Kern, Wolfgang
Schnittger, Susanne
Haferlach, Torsten
Haferlach, Claudia
BLOOD, 2011, 118 (21) : 1040 - 1040
[8] Acute myeloid leukemia with concurrent NPM1 and RUNX1 mutations
Zuo, Zhuang
Medeiros, L. Jeffrey
Yin, C. Cameron
LEUKEMIA RESEARCH REPORTS, 2023, 20
[9] Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: A single institution experience
Gaut, Daria
Burkenroad, Aaron
Duong, Tuyen
Feammelli, Jesse
Sasine, Joshua
Schiller, Gary
LEUKEMIA RESEARCH, 2020, 90
[10] Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia
Bouligny I.M.
Murray G.
Doyel M.
Patel T.
Boron J.
Tran V.
Gor J.
Hang Y.
Alnimer Y.
Ho T.
Zacholski K.
Venn C.
Wages N.A.
Grant S.
Maher K.R.
Medical Oncology, 41 (3)

← 1 2 3 4 5 →